← Back to Search

Virus Therapy

PUL-042 for Hematological Disorders

Phase 1
Waitlist Available
Led By Roy F Chemaly, MD, MPH
Research Sponsored by Pulmotect, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 weeks
Awards & highlights
No Placebo-Only Group

Summary

Subjects with hematologic malignancies or recipients of a first allogenic or autologus hematopoietic stem cell transplant, without any evidence or respiratory infection, will receive 4 doses of PUL-042 Inhalation Solution over a 2 week period. Subjects will be evaluated for tolerability of the drug. If tolerated, dose escalation may occur with up to 4 dose levels tested

Eligible Conditions
  • Hematological Disorders
  • Blood Diseases
  • Bone Marrow Transplant

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Forced Expiratory Volume in one Second (FEV1)
Secondary study objectives
Proteome

Side effects data

From 2021 Phase 2 trial • 101 Patients • NCT04312997
6%
Nausea
4%
Chest discomfort
4%
Chills
2%
COVID-19
100%
80%
60%
40%
20%
0%
Study treatment Arm
PUL-042 Inhalation Solution
Sterile Saline for Inhalation

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: PUL-042Experimental Treatment1 Intervention
PUL-042 Inhalation Solution

Find a Location

Who is running the clinical trial?

Pulmotect, Inc.Lead Sponsor
6 Previous Clinical Trials
496 Total Patients Enrolled
National Heart, Lung, and Blood Institute (NHLBI)NIH
3,936 Previous Clinical Trials
47,792,653 Total Patients Enrolled
Cancer Prevention Research Institute of TexasOTHER
53 Previous Clinical Trials
99,044 Total Patients Enrolled
~0 spots leftby Mar 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top